Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms of Multiple Individually Titrated Doses of Radiprodil in Children with GRIN-related Disorder

Next Previous
Trial Profile

A Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms of Multiple Individually Titrated Doses of Radiprodil in Children with GRIN-related Disorder

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 20 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Radiprodil (Primary) ; Radiprodil (Primary) ; Radiprodil (Primary)
  • Indications Behavioural disorders; Movement disorders; Seizures; Sleep disorders
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms Honeycomb Study
  • Sponsors GRIN Therapeutics

Most Recent Events

  • 13 May 2025 According to a GRIN Therapeutics media release, company announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to radiprodil was supported by positive data from the Phase 1b Honeycomb study in pediatric patients with confirmed GoF mutations across GRIN genotypes.
  • 09 Dec 2024 According to a GRIN Therapeutics media release, company presented additional topline data as a late-breaking poster at the American Epilepsy Society (AES) Annual Meeting in Los Angeles, California.
  • 21 Nov 2024 According to a GRIN Therapeutics media release, company will present data from this study at the American Epilepsy Society's (AES) Annual Meeting, December 6-10 in Los Angeles, CA.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top